Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $35.7 million.

  • Exagen's Cash & Current Investments rose 6201.5% to $35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year increase of 6201.5%. This contributed to the annual value of $22.0 million for FY2024, which is 3961.58% down from last year.
  • Exagen's Cash & Current Investments amounted to $35.7 million in Q3 2025, which was up 6201.5% from $30.0 million recorded in Q2 2025.
  • Exagen's 5-year Cash & Current Investments high stood at $118.1 million for Q1 2021, and its period low was $11.2 million during Q1 2025.
  • For the 5-year period, Exagen's Cash & Current Investments averaged around $55.6 million, with its median value being $36.5 million (2023).
  • In the last 5 years, Exagen's Cash & Current Investments skyrocketed by 7676.61% in 2021 and then tumbled by 5897.44% in 2025.
  • Quarter analysis of 5 years shows Exagen's Cash & Current Investments stood at $99.4 million in 2021, then tumbled by 37.26% to $62.4 million in 2022, then crashed by 41.51% to $36.5 million in 2023, then tumbled by 39.62% to $22.0 million in 2024, then soared by 62.01% to $35.7 million in 2025.
  • Its Cash & Current Investments stands at $35.7 million for Q3 2025, versus $30.0 million for Q2 2025 and $11.2 million for Q1 2025.